Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics
by
Rainer M, Mucke HA, Kruger-Rainer C,
Kraxberger E, Haushofer M, Jellinger KA.
Memory-Clinic and Department of Psychiatry,
Donauspital, Sozialmedizinisches Zentrum Ost,
Vienna, Austria.
J Neural Transm. 2001;108(11):1327-33

ABSTRACT

In a cross-sectional study of outpatients diagnosed with dementia of the Alzheimer type who had been treated with a broad variety of drugs supposed to improve cognition or to delay cognitive decline, we have investigated the effects of abruptly discontinuing therapy on cognition. Termination of therapy with any cholinesterase inhibitor was associated with a cognitive decline during the following 6-7 weeks which was significantly more pronounced than that experienced by patients who had received nootropic drugs or calcium channel blockers (3.41 vs. 1.17 points on the ADAS-Cog scale; -1.14 vs. -0.06 points on the MMSE scale). This effect was not modified by gender, apolipoprotein E genotype, or the extent of ventricular enlargement on CT scans. Its magnitude was comparable to the cognitive response observed in published clinical trials when cholinesterase therapy commenced, and also with the data obtained during a 6-week placebo washout phase.

Tacrine
Lecithin
Acetylcholine
New brain cells
The memory switch?
Dumb-drug euphoria
Cholinesterase inhibitors
Memory-enhancing Neotrofin in Alzheimer's disease

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Utopian Pharmacology
SMART DRUGS 2: review
The Hedonistic Imperative
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family